The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

Nat Commun. 2022 Dec 9;13(1):7619. doi: 10.1038/s41467-022-35192-7.

Abstract

Myelodysplastic syndromes (MDS) are hematopoietic stem cell (HSC) malignancies characterized by ineffective hematopoiesis, with increased incidence in older individuals. Here we analyze the transcriptome of human HSCs purified from young and older healthy adults, as well as MDS patients, identifying transcriptional alterations following different patterns of expression. While aging-associated lesions seem to predispose HSCs to myeloid transformation, disease-specific alterations may trigger MDS development. Among MDS-specific lesions, we detect the upregulation of the transcription factor DNA Damage Inducible Transcript 3 (DDIT3). Overexpression of DDIT3 in human healthy HSCs induces an MDS-like transcriptional state, and dyserythropoiesis, an effect associated with a failure in the activation of transcriptional programs required for normal erythroid differentiation. Moreover, DDIT3 knockdown in CD34+ cells from MDS patients with anemia is able to restore erythropoiesis. These results identify DDIT3 as a driver of dyserythropoiesis, and a potential therapeutic target to restore the inefficient erythroid differentiation characterizing MDS patients.

MeSH terms

  • Adult
  • Aged
  • Erythropoiesis / genetics
  • Gene Expression Regulation
  • Hematopoietic Stem Cells / metabolism
  • Humans
  • Myelodysplastic Syndromes* / pathology
  • Transcription Factor CHOP / genetics
  • Transcription Factors* / genetics
  • Transcription Factors* / metabolism

Substances

  • Transcription Factors
  • DDIT3 protein, human
  • Transcription Factor CHOP